Real-World Data Supports Safety and Efficacy of AbbVie's Vyalev for Advanced Parkinson's Disease

Interim 12-month results from AbbVie's ROSSINI study, presented at the European Academy of Neurology (EAN) 2026, indicate that Vyalev (foslevodopa/foscarbidopa) is a clinically meaningful real-world treatment option for advanced Parkinson's disease. The continuous subcutaneous infusion therapy demonstrated sustained improvements in motor fluctuations, non-motor symptoms, and quality-of-life outcomes over one year, with a safety profile consistent with expectations.

Context

AbbVie's Vyalev is a combination therapy designed to address both motor and non-motor symptoms of advanced Parkinson's disease. The ROSSINI study's interim results were presented at a prominent neurology conference, underscoring the relevance of ongoing research in this area. Prior treatments have often had limitations, making the evaluation of new therapies essential.

Why it matters

The findings from the ROSSINI study highlight the potential of Vyalev as a significant treatment option for individuals with advanced Parkinson's disease. This is important as Parkinson's disease can severely impact quality of life, and effective management options are crucial for patients. The study's results may influence treatment protocols and patient care strategies moving forward.

Implications

If Vyalev is widely adopted, it could lead to improved management of advanced Parkinson's disease for many patients. This may reduce the burden on caregivers and healthcare systems by improving patient outcomes. The safety profile consistent with expectations suggests that it could be a viable option for a broad range of patients.

What to watch

As further data from the ROSSINI study becomes available, it will be important to monitor how these findings are received by the medical community. Additionally, regulatory reviews and potential approvals for Vyalev could occur in the near future. Observing how healthcare providers integrate this therapy into treatment plans will also be key.